AR130144A1 - Proteínas de unión a nkg2d, cd16 y ceacam5 - Google Patents
Proteínas de unión a nkg2d, cd16 y ceacam5Info
- Publication number
- AR130144A1 AR130144A1 ARP230102084A ARP230102084A AR130144A1 AR 130144 A1 AR130144 A1 AR 130144A1 AR P230102084 A ARP230102084 A AR P230102084A AR P230102084 A ARP230102084 A AR P230102084A AR 130144 A1 AR130144 A1 AR 130144A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- nos
- group
- Prior art date
Links
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 title abstract 5
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 title abstract 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 title abstract 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 title abstract 3
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 title abstract 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 title abstract 3
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 title abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 15
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 101100407152 Arabidopsis thaliana PBL7 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se describen proteínas de unión multiespecíficas que se unen a NKG2D, CD16 y CEACAM5, así como composiciones farmacéuticas y métodos terapéuticos útiles para el tratamiento del cáncer. Reivindicación 1: Una proteína que comprende: (a) un primer sitio de unión a antígeno que se une a NKG2D; (b) un segundo sitio de unión a antígeno que se une a CEACAM5; y (c) un tercer sitio de unión a antígeno, o un dominio Fc de anticuerpo o una parte del mismo, que se une a CD16, en donde: el segundo sitio de unión a antígeno que se une a CEACAM5 comprende un dominio variable de cadena pesada (VH) que comprende una región determinante de complementariedad (CDR) 1 (CDRH1), CDRH2 y CDRH3, y un dominio variable de cadena ligera (VL) que comprende una CDR 1 (CDL1), CDRL2 y CDRL3, en donde: (i) la CDRH1 comprende una secuencia de aminoácidos seleccionada del grupo que consiste en: las SEQ ID Nº 3 y 102; (ii) la CDRH2 comprende una secuencia de aminoácidos seleccionada del grupo que consiste en: las SEQ ID Nº 37, 104 y 718; (iii) la CDRH3 comprende una secuencia de aminoácidos seleccionada del grupo que consiste en: las SEQ ID Nº 6, 38 y 105; (iv) la CDRL1 comprende una secuencia de aminoácidos seleccionada del grupo que consiste en: las SEQ ID Nº 7, 40 y 107; (v) la CDRL2 comprende una secuencia de aminoácidos seleccionada del grupo que consiste en: las SEQ ID Nº 8, 41 y 108; y (vi) la CDRL3 comprende una secuencia de aminoácidos seleccionada del grupo que consiste en: las SEQ ID Nº 9, 42 y 109. Reivindicación 35: Una proteína que comprende: (a) un primer polipéptido que comprende la secuencia de aminoácidos de la SEQ ID Nº 549; (b) un segundo polipéptido que comprende la secuencia de aminoácidos de la SEQ ID Nº 550; y (c) un tercer polipéptido que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en: las SEQ ID Nº 702, 706, 709 y 713. Reivindicación 53: Una proteína que comprende un sitio de unión a antígeno que se une a CEACAM5, en donde el sitio de unión a antígeno comprende un VH que comprende una CDRH1, CDRH2 y CDRH3, y un VL que comprende una CDRL1, CDRL2 y CDRL3, en donde: (i) la CDRH1 comprende una secuencia de aminoácidos seleccionada del grupo que consiste en: las SEQ ID Nº 3 y 102; (ii) la CDRH2 comprende una secuencia de aminoácidos seleccionada del grupo que consiste en: las SEQ ID Nº 37, 104 y 718; (iii) la CDRH3 comprende una secuencia de aminoácidos seleccionada del grupo que consiste en: las SEQ ID Nº 6, 38 y 105; (iv) la CDRL1 comprende una secuencia de aminoácidos seleccionada del grupo que consiste en: las SEQ ID Nº 7, 40 y 107; (v) la CDRL2 comprende una secuencia de aminoácidos seleccionada del grupo que consiste en: las SEQ ID Nº 8, 41 y 108; y (vi) la CDRL3 comprende una secuencia de aminoácidos seleccionada del grupo que consiste en: las SEQ ID Nº 9, 42 y 109.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263396910P | 2022-08-10 | 2022-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130144A1 true AR130144A1 (es) | 2024-11-06 |
Family
ID=87974268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102084A AR130144A1 (es) | 2022-08-10 | 2023-08-08 | Proteínas de unión a nkg2d, cd16 y ceacam5 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240124607A1 (es) |
| AR (1) | AR130144A1 (es) |
| AU (1) | AU2023323773A1 (es) |
| CO (1) | CO2025001294A2 (es) |
| TW (1) | TW202417483A (es) |
| WO (1) | WO2024035662A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116199777B (zh) * | 2021-12-01 | 2025-01-28 | 北京免疫方舟医药科技有限公司 | 抗hNKG2D抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3009455A1 (en) | 2009-09-16 | 2016-04-20 | Immunomedics Inc. | Class i anti-cea antibodies and uses thereof |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| RS60043B1 (sr) | 2012-11-20 | 2020-04-30 | Sanofi Sa | Anti-ceacam5 antitela i njihova primena |
| WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| CN107530424A (zh) | 2015-02-20 | 2018-01-02 | 俄亥俄州国家创新基金会 | 针对nkg2d和肿瘤相关抗原的二价抗体 |
| CA3053010A1 (en) | 2017-02-08 | 2018-08-16 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN112661853A (zh) * | 2017-02-27 | 2021-04-16 | 蜻蜓疗法股份有限公司 | 靶向caix、ano1、间皮素、trop2或紧密连接蛋白18.2的多特异结合蛋白 |
| FI3749346T3 (fi) | 2018-02-08 | 2024-09-04 | Dragonfly Therapeutics Inc | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät |
| JP7554781B2 (ja) * | 2019-06-04 | 2024-09-20 | 普米斯生物技術（珠海）有限公司 | 抗ｃｅａｃａｍ５モノクローナル抗体およびその調製方法およびその使用 |
| US20230257467A1 (en) * | 2020-08-05 | 2023-08-17 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and egfr |
-
2023
- 2023-08-08 AU AU2023323773A patent/AU2023323773A1/en active Pending
- 2023-08-08 AR ARP230102084A patent/AR130144A1/es unknown
- 2023-08-08 US US18/366,876 patent/US20240124607A1/en active Pending
- 2023-08-08 TW TW112129740A patent/TW202417483A/zh unknown
- 2023-08-08 WO PCT/US2023/029676 patent/WO2024035662A2/en active Application Filing
-
2025
- 2025-02-05 CO CONC2025/0001294A patent/CO2025001294A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024035662A2 (en) | 2024-02-15 |
| US20240124607A1 (en) | 2024-04-18 |
| WO2024035662A3 (en) | 2024-05-16 |
| TW202417483A (zh) | 2024-05-01 |
| CO2025001294A2 (es) | 2025-02-13 |
| AU2023323773A1 (en) | 2025-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL302078A (en) | Anti-ccr8 monoclonal antibodies and uses thereof | |
| PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
| PE20231851A1 (es) | Proteinas que se unen a nkg2d, cd16 y clec12a | |
| IL257281A (en) | Anti-pd-1 antibodies and methods of using them | |
| PE20221151A1 (es) | Anticuerpos anti-cd96 y sus metodos de uso | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| RU2017104813A (ru) | Молекулы со специфичностью к cd45 и cd79 | |
| CL2010001544A1 (es) | Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma. | |
| JP2024175003A5 (es) | ||
| JP2020516240A5 (es) | ||
| PE20221869A1 (es) | Moleculas de union a antigeno biespecificas dirigidas a ox40 y fap | |
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
| AR082194A1 (es) | Anticuerpos anti-ron | |
| RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| AR110659A1 (es) | Proteínas de unión a antígenos anti-neuropilin y método para su uso | |
| JP2020500834A5 (es) | ||
| RU2018126318A (ru) | Молекулы полиспецифичных антител, имеющие специфичность к tnf-альфа, il-17a и il-17f | |
| JP2023071956A5 (es) | ||
| HRP20192038T1 (hr) | Protutijela receptora anti-epidermalnog faktora rasta (egfr) | |
| PE20220487A1 (es) | Anticuerpos anti-ms4a4a y metodos de uso de los mismos | |
| AR123306A1 (es) | Anticuerpos fgfr3 y métodos de uso | |
| ZA202211246B (en) | Bispecific antibody | |
| JP2017521054A5 (es) |